Welcome to Nino’s News. Our guest blogger, Anthony “Nino” Sireci, M.D. is vice president, clinical biomarker and diagnostics development, Loxo Oncology at Lilly. Dr. Sireci is a board-certified Clinical Pathologist and a practicing molecular pathologist. Prior to joining Loxo, he was an Assistant Professor of Pathology and Cell Biology at Columbia University and a medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center.
Nino's News

The Role of Biomarker Testing in Early-Stage NSCLC: Why It’s Not Just for Advanced Disease
The Role of Biomarker Testing in Early-Stage NSCLC: Why It’s Not Just for Advanced Disease

Looking Ahead: The Future of Diagnostic Testing for Patients
Looking Ahead: The Future of Diagnostic Testing for Patients

Finding the Right Time to Ask About Biomarker Testing
Finding the Right Time to Ask About Biomarker Testing

Understanding the Role of a Care Team in Treatment Planning
Understanding the Role of a Care Team in Treatment Planning

The Importance of Biomarker Testing When Facing RET-Altered Cancers
The Importance of Biomarker Testing When Facing RET-Altered Cancers
You might also like: Why lung cancer biomarker testing matters for RET-positive patients.
